Authors: Lepri, AC Phillips, AN Monforte, AD Castelli, F Antinori, A de Luca, A Pezzotti, P Alberici, F Cargnel, A Grima, P Piscopo, R Prestileo, T Scalise, G Vigevani, M Moroni, M

Citation: Ac. Lepri et al., When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study, AIDS, 15(8), 2001, pp. 983-990

Authors: Prestileo, T Mazzola, G Di Lorenzo, F Colletti, P Vitale, F Ferraro, D Di Stefano, R Camma, C Craxi, A

Citation: T. Prestileo et al., Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients, INT J ANT A, 16(3), 2000, pp. 373-378

Authors: Pezzotti, P Monforte, AD Bugarini, R Rezza, G Arici, C Angarano, G Borderi, M Alberici, F Armignacco, O Menichetti, F Prestileo, T Sighinolfi, L Sinicco, A Resta, F Vigevani, M Ippolito, G

Citation: P. Pezzotti et al., Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?, EUR J EPID, 16(10), 2000, pp. 919-926

Authors: Perna, AM Bonura, F Vitale, F Viviano, E Di Benedetto, MA Ajello, F Villafrate, MR Prestileo, T Mancuso, S Goedert, JJ Romano, N

Citation: Am. Perna et al., Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily, INT J EPID, 29(1), 2000, pp. 175-179